Table 1.
Clinical characteristics of study sample
| WHO grade | n | Sex (M/F) | Histology/WHO grade | n | Median age (y) | Median PFS (wk) | No tumor regrowth | Median OS (wk) | Alive at LO |
|---|---|---|---|---|---|---|---|---|---|
| II | 62 | 40/22 | A/2 | 55 | 41(2–70) | 195a (11–308) | 41/55 | 196(2–308) | 45/55 |
| O/2 | 7 | 48(9–65) | 232 (84–310) | 1/7 | 232(150–310) | 1/7 | |||
| III | 29 | 18/11 | AA/3 | 28 | 48.5(19–69) | 69b (6–306) | 8/28 | 101(2–355) | 8/28 |
| OA/3 | 1 | 22 | 145 | 0/1 | 175 | 1/1 | |||
| IV | 79 | 52/27 | pGBM | 73 | 53(11–79) | 29c (11–242) | 6/73 | 66(2–242) | 9/73 |
| sGBM | 6 | 45.5(38–61) | 14d (9–24) | 1/6 | 41(15–87) | 0/6 |
n case number; M male, F female, LO last observation, A astrocytoma, O oligodendroglioma, AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, pGBM primary glioblastoma, sGBM secondary glioblastoma
aPFS of two patients could not be assessed
bPFS of two patients could not be assessed
cPFS of thirteen patients could not be assessed
dPFS of one patients could not be assessed